Literature DB >> 12183524

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.

Sukumar Pal1, Heather L Davis, Ellena M Peterson, Luis M de la Maza.   

Abstract

Recently, we have shown that a vaccine consisting of a purified preparation of the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) and Freund's adjuvant can protect mice against a genital challenge. Here, we wanted to determine if CpG motifs could be used as an immune modulator to the MOMP to induce protection in mice against an intranasal (i.n.) challenge. One-week-old BALB/c mice were immunized intramuscularly and subcutaneously either once or three times at 2-week intervals with MOMP and CpG suspended in aluminum hydroxide (alum). Negative controls received ovalbumin, CpG, and alum. Positive controls were immunized i.n. with C. trachomatis MoPn elementary bodies (EB). Six weeks after the last immunization, mice were challenged i.n. with 10(4) inclusion-forming units (IFU) of the C. trachomatis MoPn serovar. Mice that received MOMP, CpG, and alum had a strong immune response, as shown by a high titer of serum antibodies to Chlamydia and significant lymphoproliferation of T-cells following stimulation with C. trachomatis EB. After the i.n. challenge mice immunized with MOMP, CpG, and alum showed significantly less body weight loss than the corresponding control mice immunized with ovalbumin, CpG, and alum. Ten days after the challenge the animals were euthanized, their lungs were weighed, and the numbers of IFU in the lungs were determined. The average weight of the lungs of the mice immunized with MOMP, CpG, and alum was significantly less than average weight of the lungs of the mice immunized with ovalbumin, CpG, and alum. Also, the average number of IFU recovered per mouse immunized with MOMP, CpG, and alum was significantly less than the average number of IFU per mouse detected in the mice inoculated with ovalbumin, CpG, and alum. In conclusion, our data show that CpG sequences can be used as an effective adjuvant with the C. trachomatis MoPn MOMP to elicit a protective immune response in mice against a chlamydial respiratory challenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183524      PMCID: PMC128273          DOI: 10.1128/IAI.70.9.4812-4817.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  CpG DNA as mucosal adjuvant.

Authors:  M J McCluskie; H L Davis
Journal:  Vaccine       Date:  1999-09       Impact factor: 3.641

Review 2.  Chlamydial vaccines--future trends.

Authors:  M E Ward
Journal:  J Infect       Date:  1992-07       Impact factor: 6.072

3.  Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein.

Authors:  M Tuffrey; F Alexander; W Conlan; C Woods; M Ward
Journal:  J Gen Microbiol       Date:  1992-08

4.  Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes.

Authors:  W Baehr; Y X Zhang; T Joseph; H Su; F E Nano; K D Everett; H D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

5.  Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.

Authors:  S Pal; I Theodor; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

Authors:  E M Peterson; G M Zhong; E Carlson; L M de la Maza
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

7.  Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge.

Authors:  S Pal; K M Barnhart; Q Wei; A M Abai; E M Peterson; L M de la Maza
Journal:  Vaccine       Date:  1999-02-05       Impact factor: 3.641

9.  CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Authors:  R D Weeratna; M J McCluskie; Y Xu; H L Davis
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

10.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

View more
  33 in total

1.  A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males.

Authors:  Sukumar Pal; Annahita K Sarcon; Luis M de la Maza
Journal:  Vaccine       Date:  2010-10-13       Impact factor: 3.641

2.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

3.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

4.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

6.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

7.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

8.  Mapping immunodominant antigens and H-2-linked antibody responses in mice urogenitally infected with Chlamydia muridarum.

Authors:  Hao Zeng; Shuping Hou; Siqi Gong; Xiaohua Dong; Quanming Zou; Guangming Zhong
Journal:  Microbes Infect       Date:  2012-03-03       Impact factor: 2.700

9.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

10.  Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.

Authors:  Rhea N Coler; Ajay Bhatia; Jean-Francois Maisonneuve; Peter Probst; Brenda Barth; Pamela Ovendale; Hang Fang; Mark Alderson; Yves Lobet; Joe Cohen; Pascal Mettens; Steven G Reed
Journal:  FEMS Immunol Med Microbiol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.